Loading page…

Sandu Pharmaceuticals Ltd (SANDUPHQ) · mywealthgrid

About

Sandu Pharmaceuticals Ltd operates in Pharmaceuticals within the Healthcare sector.

Face value: ₹10

Market cap

₹35 Cr

P/E

22.9×

P/B

0.8×

Dividend yield

4.9%

ROE

3.8%

ROCE

5.3%

Debt / equity

OPM

4.1%

EPS (TTM)

₹1.6

Book value

₹43.5

52-week high

₹48.0

52-week low

₹30.5

₹36.5-23.8%1Y

Beta

0.73

Damps index moves

Volatility (1y)

44.5%

Annualised, daily returns

RSI (14)

37.6

Neither overbought nor oversold

Rel. strength (1y)

-32.6%

Behind the market

Beta is measured against NIFTY 50 over three years of weekly returns — 1 moves with the index, above 1 amplifies it, below 1 damps it.

Quick read

rule-based

Pros

+Almost debt-free (debt/equity 0)
+Comfortable interest coverage of 22.6×
+Dividend yield of 4.9%

Cons

−Low return on equity of 3.8% (3-yr avg)
−Thin operating margin of 4.1%
−Modest revenue growth of 0.9% a year over the last 3 years
−Promoter holding fell 5.1 pts over the last year

Research score

Structured signal from quality, growth, valuation and momentum.

31/100

Business quality: 40
Growth: 3

Revenue & net profit

₹ crore, by fiscal year

RevenuePAT

Margins

% of revenue, by fiscal year

OPMPAT margin

Peers

Comparable companies from the narrowest available industry classification.

Screen this industry Compare top 5 side-by-side

Company	Mkt Cap	EV	Revenue	EBITDA	OPM	PAT	NPM	ROCE	ROE	WC Days
Torrent Pharmaceuticals LimitedTORNTPHARMTORNTPHARM	₹1,61,325 Cr	₹1,76,123 Cr	₹15,723 Cr	₹5,191 Cr	32.6%	₹2,181 Cr	15.3%	14.5%	27.1%	163
Zydus Lifesciences LimitedZYDUSLIFEZYDUSLIFE	₹1,14,284 Cr	₹1,26,053 Cr	₹28,592 Cr	₹8,316 Cr	31.2%	₹4,513 Cr	18.9%	23.4%	19.7%	212
Laurus Labs LimitedLAURUSLABSLAURUSLABS	₹1,07,176 Cr	₹1,09,573 Cr	₹7,270 Cr	₹2,034 Cr	26.1%	₹1,093 Cr	13.1%	21.3%	18.2%	263
Mankind Pharma LimitedMANKINDMANKIND	₹1,04,696 Cr	₹1,11,007 Cr	₹14,738 Cr	₹3,827 Cr	25.3%	₹2,068 Cr	13.6%	14.2%	12.5%	117
Aurobindo Pharma LimitedAUROPHARMAAUROPHARMA	₹97,389 Cr	₹1,05,065 Cr	₹34,935 Cr	₹7,085 Cr	20.3%	₹3,713 Cr	10.4%	14.7%	9.9%	252
Lupin LimitedLUPINLUPIN	₹92,866 Cr	₹98,777 Cr	₹29,967 Cr	₹9,538 Cr	31.5%	₹5,529 Cr	19.2%	34.2%	26.9%	181
Glenmark Pharmaceuticals LimitedGLENMARKGLENMARK	₹65,781 Cr	₹65,781 Cr	₹17,737 Cr	₹4,797 Cr	26.9%	₹1,496 Cr	8%	37.8%	0%	83
Alkem Laboratories LimitedALKEMALKEM	₹62,431 Cr	₹64,055 Cr	₹15,081 Cr	₹3,032 Cr	20.4%	₹2,158 Cr	16%	21.5%	17.8%	152
Biocon LimitedBIOCONBIOCON	₹60,413 Cr	₹75,238 Cr	₹17,321 Cr	₹3,536 Cr	20.4%	₹495 Cr	2.2%	3.9%	1.4%	85
Abbott India LimitedABBOTINDIAABBOTINDIA	₹56,901 Cr	—	₹4,310 Cr	₹921 Cr	27.3%	₹691 Cr	22.4%	44.1%	34.5%	110
Ipca Laboratories LimitedIPCALABIPCALAB	₹49,299 Cr	₹50,003 Cr	₹10,126 Cr	₹2,232 Cr	20.5%	₹1,310 Cr	12.3%	17.8%	15.2%	308
Gland Pharma LimitedGLANDGLAND	₹47,428 Cr	₹47,671 Cr	₹6,725 Cr	₹1,751 Cr	25.3%	₹1,129 Cr	16%	14.8%	10.5%	255

Loading peers…

Financials

Reported profit and loss, balance sheet, cash flow and growth history.

Annual Quarterly

Consolidated Standalone

Consolidated figures · ₹ crore

₹ Cr	Mar 2022	Mar 2023	Mar 2024	Mar 2025
	65	65	67	67
COGS	31	31	33	32
Gross profit	34	34	35	35
	—	32	32	32
Operating profit (EBITDA)	—	2	2	3
OPM %	—	3.8%	3.4%	4.1%
Depreciation	1	1	1	1
Interest	0	0	0	0
	0	0	0	0
Profit before tax	—	2	2	2
Tax	—	1	1	1
Tax %	—	31.5%	29.5%	28.2%
	2	2	1	2
PAT margin %	2.3%	2.3%	2.2%	2.3%
EPS (₹)	—	—	1.5	1.6
EPS adjusted (₹)	—	1.6	1.5	1.6
	—	—	53%	49.7%
Annual report	Annual report for Mar 2022	Annual report for Mar 2023	Annual report for Mar 2024	Annual report for Mar 2025

₹ Cr	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Equity capital	0	10	10	10
Reserves	—	30	31	32
	—	0	0	0
	17	15	12	14
Total equity & liabilities	17	54	52	56
	16	17	18	18
CWIP	—	0	0	0
Investments	—	10	10	11
	1	27	24	26
Total assets	17	54	52	56

₹ Cr	Mar 2023	Mar 2024	Mar 2025
	0	1	1
	1	-1	-0
	1	-1	-0
Net cash flow	1	-1	0
Free cash flow	-1	-1	0
CFO / Operating profit %	8.8%	33.2%	34.4%

Compounded sales growth

7 years: —
5 years: —
3 years: 1%
1 year: -0%

Compounded profit growth

7 years: —
5 years: —
3 years: 1%
1 year: 6%

Stock price CAGR

10 years: —
5 years: -6%
3 years: -22%
1 year: -24%

Return on equity

7 years

Loading financials…

Ratios

Annual operating, return, leverage and working-capital ratios.

Consolidated Standalone

Consolidated figures

Ratio	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Margins
Gross margin %	52.3%	52.3%	51.6%	52.2%
EBITDA margin %	—	3.8%	3.4%	4.1%
EBIT margin %	—	3%	2.5%	3.1%
PAT margin %	2.3%	2.3%	2.2%	2.3%
Working capital
Receivable days	—	27	26	26
Inventory days	—	168	137	161
Payable days	—	98	47	51
NWC days	—	96	117	136
Leverage
Current ratio	—	1.84	2.1	2.18
Debt to EBITDA	—	0	0	0
Debt to equity	—	0	0	0
Interest coverage	-2.4	28.8	35.5	22.6
Asset turnover	3.86	1.21	1.28	1.21
Return ratios
Return on assets %	9%	2.8%	2.8%	2.8%
Return on capital employed %	—	5.7%	5.2%	5.3%
Return on equity %	—	3.9%	3.6%	3.7%

Derived from reported annual statements. ROCE uses EBIT over capital employed (total assets less current liabilities). Day counts average the opening and closing balance; receivables turn on revenue, inventory and payables on cost of goods sold.

Loading ratios…

Shareholding

Quarterly ownership, named holders, insider transactions and disclosed deals.

Quarterly Annual

Every quarter filed · % of equity

Holder (%)	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	52.41%	42.9%	42.9%	42.9%	42.9%	42.9%	42.9%	42.9%	42.9%	37.79%	37.79%	37.79%
FII	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
	0.01%	0.01%	0.01%	0.01%	0.01%	0.01%	0.01%	0.01%	0.01%	0.01%	0.01%	0.01%
Government	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
	47.58%	57.09%	57.09%	57.09%	57.09%	57.09%	57.09%	57.09%	57.09%	62.2%	62.2%	62.2%
No. of shareholders	—	—	—	—	—	—	—	—	10,284	10,284	10,298	10,268

Promoter holding down 14.62 percentage points since Sep 2023.

2 deals · 19 Mar 2024 – 19 Mar 2024

Date	Client	Type	Venue	Side	Quantity	Price	Value
19 Mar 2024	TRANS SCAN SECURITIES PVT LTD	Bulk	BSE	Buy	1,06,000	₹55.88	₹0.59 Cr
19 Mar 2024	DPS TRADELINK PRIVATE LIMITED	Bulk	BSE	Sell	1,04,061	₹55.85	₹0.58 Cr

1–2 of 2

1 / 1

Bulk deals are a client trading over 0.5% of the equity in a session, aggregated across their trades; block deals are single negotiated trades in the exchange’s block window. Each is reported by the exchange it was crossed on, so NSE and BSE rows are separate trades rather than the same trade twice.

Mr. BALRAM VISWANATHANNon-Executive - Independent Director-Chairperson
Mr. AJIT RAJARAM KANTAKNon-Executive - Independent Director
Mr. SHASHANK SANDUNon-Executive - Non Independent Director
Mr. VIJAY KOTTAPALLINon-Executive - Independent Director
Mrs. JAYSHREE BHASKER SANDUNon-Executive - Non Independent Director
Mrs. Neeti Madan KapreNon - Executive Independent Director
Ms. Pratika MhambrayCompany Secretary & Compliance Officer

Current officeholders as filed with BSE. A person holding two offices is listed once per office.

Loading shareholding…

F&O

Current futures and options contracts with compact option-chain pages.

Not in the F&O segment

Only about 210 stocks have listed futures and options. Contracts appear here for those, refreshed after each close.

Loading f&o…

Fund holders

Mutual-fund schemes that disclosed a holding in the company.

No fund holdings on record

No scheme among the 32 fund houses on record reported a position in Sandu Pharmaceuticals Ltd. Portfolios are published monthly by each AMC; coverage is still partial.

Loading fund holders…

Documents

Annual reports, exchange filings, offer documents, ratings and earnings-call material.

Announcements

Annual reports

Documents link to external sources (exchange filings, company investor pages).

Loading documents…

Events

Upcoming dates and the company’s corporate-action history.

6

Final dividend4 Sept 2026 · ex-date₹1
Final dividend18 Sept 2025 · ex-date₹0.8
Final dividend19 Sept 2024 · ex-date₹0.8
Final dividend18 Sept 2023 · ex-date₹0.75
Dividend dividend23 Sept 2022 · ex-date₹0.75
Dividend dividend22 Sept 2021 · ex-date₹0.5

1

Board meeting to consider results11 Aug 2026

Loading events…

Announcements

Latest exchange announcements, filings and downloadable documents.

1 month 3 months 6 months 1 year All

49 announcementsExport CSV

11 Aug 2026, 6:05 pmCorp. Action

Intimation About The Record Date

Record Date PDF

11 Aug 2026, 6:03 pmCorp. Action

Intimation About Book Closure For AGM

Book Closure PDF

11 Aug 2026, 5:59 pmCompany Update

Outcome And Results Of The Board Meeting Dated 11.08.2026 Was Submitted On Time But Inadvertently No Digital Signature Was Affixed On The Covering Letter Further There Is No Change In The Contents Of The Outcome

General PDF

11 Aug 2026, 5:46 pmResult

Unaudited Financials For Q Ended 30.06.2026

Financial Results PDF

11 Aug 2026, 5:39 pmCompany Update

Outcome Of The Board Meeting

General PDF

11 Aug 2026, 5:24 pmBoard Meeting

Board Meeting Outcome for Outcome Of The Board Meeting Dated 11.08.2026

Outcome of Board Meeting PDF

3 Aug 2026, 2:52 pmBoard Meeting

Board Meeting Intimation for To Consider And Approve The Standalone Unaudited Financial Results Of The Company For The Quarter Ended 30Th June, 2026.

Exchange filing PDF

11 Jul 2026, 5:36 pmCompany Update

Announcement Under Regulation 30-Reconstitution Of Committees Of Board-Audit/Nomination/Stakeholders

General PDF

Date	Category	Subject	Filing
11 Aug 2026, 6:05 pm	Corp. Action Record Date	Intimation About The Record Date	PDF
11 Aug 2026, 6:03 pm	Corp. Action Book Closure	Intimation About Book Closure For AGM	PDF

Loading announcements…

Sandu Pharmaceuticals Ltd

Sandu Pharmaceuticals Ltd

About

Risk & technicals

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Profit & loss

Balance sheet

Cash flow

Compounded returns

Compounded sales growth

Compounded profit growth

Stock price CAGR

Return on equity

Ratios

Ratio timeline

Shareholding

Quarterly record

Bulk & block deals

Board and management

F&O

Not in the F&O segment

Fund holders

No fund holdings on record

Documents

Announcements

Annual reports

Events

Dividends6

Board meetings1

Announcements

No fund holdings on record

Not in the F&O segment

Dividends6

Board meetings1

Ratio timeline

Quarterly record

Bulk & block deals

Board and management

Announcements

Annual reports

Profit & loss

Balance sheet

Cash flow

Compounded returns

Compounded sales growth

Compounded profit growth

Stock price CAGR

Return on equity

6

1

6

1